Skip to main content
. Author manuscript; available in PMC: 2010 Dec 7.
Published in final edited form as: Virology. 2009 Oct 2;395(1):97–113. doi: 10.1016/j.virol.2009.09.008

Table 3.

Bioinformatic analysis of confirmed protective CPV candidates.

CPV ORF VACCINIA
HOMOLOGUE		 VARIOLA
HOMOLOGUE		 FUNCTION OR
HOMOLOGY		 SURVIVAL1
(P-VALUE)
CPV0030a C6L D9L hypothetical protein 0.013
CPV0066a F16L C20L hypothetical protein 0.004
CPV0097b G7L H7L core protein 0.027
CPV0100a G9R H9R myristylation site,
trans-membrane
protein involved in
entry/fusion		 0.0006
CPV0110a J5L L5L myristylation site,
trans-membrane
protein of unknown
function		 0.001
CPV0120f D1R F1R mRNA capping
enzyme; termination
and initiation factor		 0.025
CPV0171a A32L A35L GTP-ATPase, DNA
packaging, virion
assembly		 0.003
CPV0225a C3L G4R Tumor necrosis
factor receptor
(TNFR) domain,
binds secreted
complement
C3b/C4b		 0.490
CPV0227c C9L B19R ankyrin-like repeats,
host range and
tissue tropism,
pathogenesis		 n.d.2
1

Footnotes:

p-values were calculated by a Mantel-Haenszel log-rank survival curve analysis

2

In the first challenge-protection assay, CPV0227c conferred protection above the 95% confidence interval, but it was not included in the confirmatory study.